SMMT · Summit Therapeutics Inc. · Exempt Offerings
$15.10
-0.23 (-1.50%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 28
95.2K
Avg daily vol (3M)
6.06M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2024-09-26 | New | Biotechnology | $234,999,889 | $234,999,889 | 06b |
| 2024-06-18 | New | Biotechnology | $199,999,998 | $199,999,998 | 06b |
| 2020-11-23 | New | Biotechnology | $50,000,000 | $50,000,000 | 06b |
| 2020-01-02 | New | Biotechnology | $47,400,000 | $47,400,000 | 06b |
Showing 1–4 of 4 filings
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
48 filings
48 filers
Visit website
Investor relations